1. Home
  2. FCF vs ORKA Comparison

FCF vs ORKA Comparison

Compare FCF & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Commonwealth Financial Corporation

FCF

First Commonwealth Financial Corporation

HOLD

Current Price

$18.42

Market Cap

1.9B

Sector

Finance

ML Signal

HOLD

Logo Oruka Therapeutics Inc.

ORKA

Oruka Therapeutics Inc.

HOLD

Current Price

$32.34

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FCF
ORKA
Founded
1934
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.6B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
FCF
ORKA
Price
$18.42
$32.34
Analyst Decision
Buy
Strong Buy
Analyst Count
4
10
Target Price
$19.75
$52.70
AVG Volume (30 Days)
753.5K
333.7K
Earning Date
04-29-2026
01-01-0001
Dividend Yield
2.93%
N/A
EPS Growth
N/A
N/A
EPS
1.04
N/A
Revenue
N/A
N/A
Revenue This Year
$16.32
N/A
Revenue Next Year
$6.25
N/A
P/E Ratio
$17.71
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.54
$5.49
52 Week High
$19.08
$36.51

Technical Indicators

Market Signals
Indicator
FCF
ORKA
Relative Strength Index (RSI) 52.93 49.09
Support Level $17.88 $31.09
Resistance Level $19.08 $33.69
Average True Range (ATR) 0.42 1.88
MACD -0.07 -0.27
Stochastic Oscillator 30.74 30.27

Price Performance

Historical Comparison
FCF
ORKA

About FCF First Commonwealth Financial Corporation

First Commonwealth Financial Corp functions in the financial services sector in the United States. Through its subsidiary, it offers a range of consumer and commercial banking services such as personal checking accounts, interest-earning checking accounts, savings accounts, insured money market accounts, investment certificates, fixed & variable rate certificates of deposit, and various kinds of loans. It also provides trust and wealth management services and offers insurance products. The company earns the majority of its revenue through net interest income.

About ORKA Oruka Therapeutics Inc.

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Share on Social Networks: